Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. - Wikidata - awgldk - TriplyDB

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.

http://www.wikidata.org/entity/Q42947260

about

Management of HBV and HBV/HDV-Associated Liver Cirrhosis KASL clinical practice guidelines: management of chronic hepatitis B Current and future directions for treating hepatitis B virus infection Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments Alpha-interferon treatment in hepatitis B Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir.Optimization therapy for the treatment of chronic hepatitis B Chronic hepatitis B: Advances in treatment.Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.Comparison of three luminescent immunoassays for hepatitis B virus surface antigen quantification during the natural history of chronic hepatitis B virus infection.Viral hepatitis B: clinical and epidemiological characteristics.CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot study Management of hepatitis B in developing countries.Hepatitis B virus genotypes and variants.Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis.Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients.A Pilot Study of MicroRNAs Expression Profile in Serum and HBsAg Particles: Predictors of Therapeutic Vaccine Efficacy in Chronic Hepatitis B Patients.Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients.Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys): TRACES Study HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients HBsAg levels in HBeAg-positive chronic hepatitis B patients with different immune conditions.Different Mechanisms May Exist for HBsAg Synthesis and Secretion During Various Phases of Chronic Hepatitis B Virus Infection.Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?Antiviral drugs for HBV liver disease.Hepatitis B therapy.Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review.Recent advances in the treatment of chronic hepatitis B.Hepatitis B surface antigen monitoring and management of chronic hepatitis B.Hepatitis B virus serology to predict antiviral response in chronic hepatitis B.Emerging pipeline drugs for hepatitis B infection.Clinical implications of HBsAg quantification in patients with chronic hepatitis B.Experimental models and therapeutic approaches for HBV.The role of HBsAg quantification for monitoring natural history and treatment outcome.Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.HBsAg quantification: useful for monitoring natural history and treatment outcome.

P2860

Q26740323-9D3C1CB1-BEFC-4948-BD0C-A30144D882C3 Q26752475-A383D0F2-74BC-4F28-A524-5DF6449C11FB Q26851240-41BC673D-87EE-4391-9B55-AFDE964F16D2 Q27008984-F71EC948-26E4-4370-8BBE-CBEFFDED585F Q33592755-0599F671-EF65-4D9E-976C-0B093CC4434A Q33604145-3D62DC96-A9A9-455B-82CB-117A2F917528 Q33626813-B9D74C0F-3DC3-4345-9090-8ED6FF77ECAA Q33660010-CE3674CE-6939-451A-8015-C5DD4E00A3C2 Q33958876-47D24732-5310-4D53-B8B8-3AD42D064FC3 Q34252292-4F2DD9AC-B8F7-426B-B8D9-6A5A6A249991 Q34592952-5D028E6B-5A49-4607-926D-73B91FAED469 Q34930389-03799CD1-7849-48D0-9AE8-FCCB9AC5DA04 Q35017075-5D58EDD5-D39C-4778-8115-DE3B01E80334 Q35635637-7D0133D5-0CBD-4E67-AA25-B35DED9082E4 Q35663838-4CC534CF-D885-4379-BCB2-6830B099B996 Q35688409-E7E86451-5590-477D-9799-778AD8537ACA Q35833216-2A28E67F-157F-431E-9BD3-D993C8B4E02F Q36351904-813685CC-3824-4630-ACAA-8CB7009DEFB5 Q36478263-50127A53-7AB9-4BEB-BFC6-2A94BF3CEE0C Q36695222-9AAB29DE-6FE3-497E-BDE9-6CCCDF8D1D74 Q36973383-73B2A9EA-7CC3-43F0-82E1-392C719319C8 Q37087279-8B503F13-B528-415E-B5AB-290C511F8831 Q37206545-9A45AC24-9E15-40DA-8591-17509C15153B Q37374481-542B6D2E-F77C-46FE-9E47-801C4A5C0028 Q37708054-3C7FA4D2-F37E-4FB9-A4E2-E742CC401143 Q37726148-2D94FB6A-260A-4AF4-B192-FCC457FB8551 Q37825532-E9C95E75-B2E4-477B-924C-8F0F7A80C9F5 Q37825909-F206F3E5-49AC-4488-83C3-58167E6A1BE5 Q37855531-017E9A00-0401-472C-B55B-478B2F0F6B78 Q37866717-EB050F1D-65BB-4D02-AEF4-69F8CD9FEFC4 Q37891094-D211C45A-9193-4844-ACE9-7B429CDA8B93 Q37892655-2918E4EF-74FF-4441-89C2-946B754B1177 Q37966704-B1391DBF-D7A2-4D16-B684-9D730A5FEA1F Q37971052-C46E2ABB-387D-4C9F-91D0-850DF713BA39 Q37994049-21CF58F6-BED8-4C59-B41C-EC5396811619 Q38035173-0ED4F95D-8198-4FAF-8E90-5D70967665B9 Q38071397-673F1E2A-859E-4FB1-8404-992D44AA36AB Q38071402-B87CC224-F5D5-4667-960B-7A95A8565665 Q38102776-D6D87DED-BCAA-43CD-B6D3-5B5FFDA1B654 Q38174257-754F847A-F883-4C57-963B-41F8AEE9E651

P2860

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.

http://www.wikidata.org/entity/Q42947260

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Early on-treatment prediction ...... sing HBsAg and HBV DNA levels.

@en

Early on-treatment prediction ...... sing HBsAg and HBV DNA levels.

@nl

type

label

Early on-treatment prediction ...... sing HBsAg and HBV DNA levels.

@en

Early on-treatment prediction ...... sing HBsAg and HBV DNA levels.

@nl

prefLabel

Early on-treatment prediction ...... sing HBsAg and HBV DNA levels.

@en

Early on-treatment prediction ...... sing HBsAg and HBV DNA levels.

@nl

P1433

Q42947260-E568FDEA-A48E-4210-9F51-56F9F83CBEB1

P1476

Q42947260-5E0D1C41-54DE-44D7-9D3D-2FC87967830B

P2093

Q42947260-1432BF5F-C558-48DF-A9DD-A5DB22B3DCB6

Q42947260-3185BCBD-E52A-4CC3-859A-1031690ECBB5

Q42947260-44F8B9CE-56DA-4C09-A4C9-1B3CD8D68BB8

Q42947260-640B25B6-08F0-4D1C-BA66-56331BEAFC4E

Q42947260-6E99A0AB-58AD-4739-A1C9-D509D8DA42ED

Q42947260-8960D1DC-4B84-4319-AD6D-FF25B107F722

Q42947260-BBED4763-124C-4431-8BE7-D9D1402A0342

Q42947260-E7390BA1-2944-4C81-BA49-80D1AFAD4861

Q42947260-F26669EE-5756-4B67-AD8D-314E3C2BFA33

Q42947260-FE9AA487-193B-4CD5-B656-2DAB9202F34F

P2860

Q42947260-0AEEEDE0-995E-47C4-A58E-7495EF10AA86

Q42947260-0C7FAF0F-DF4A-4BAE-BAE4-1E85003EE9AE

Q42947260-1862AF7C-2167-4E15-8E0C-A25CE3E5C478

Q42947260-186EE86D-6C28-4A70-BD1D-7B05B5A7499D

Q42947260-2280C14C-50D3-4B00-A286-38CAC4924235

Q42947260-27AAB265-185D-4838-B386-3684339B680A

Q42947260-296B7388-26B7-4BA3-A9C4-186925FC8FC7

Q42947260-36C0DB59-1891-4478-B646-B206FBDA0A98

Q42947260-3878F6C6-EA84-437B-AD29-E1BED9548370

Q42947260-3D5AF4D7-9AD4-4F15-8FD8-5B090824F335

P304

Q42947260-BE427C23-F4AE-4261-A905-11FEF036130C

P31

Q42947260-FF334439-6936-4FCD-820C-B9C13583C4A1

P356

Q42947260-ECEE74C7-BD91-42B1-8299-B2686F3C5460

P407

Q42947260-57B3ACBF-C7F6-4B35-8148-A445BC847E51

P433

Q42947260-BEC129DB-B6F6-498A-9FF4-3FC67897422A

P478

Q42947260-1CEE619E-94F9-410A-A56C-894B66E754F5

P50

Q42947260-28F30D08-07A6-45CA-9E03-CDB7B2962C96

Q42947260-3BB7FEC9-C67A-49B8-B47E-F2846DEA6639

Q42947260-4BAA0E87-FC48-4993-8881-30066A26E840

Q42947260-5FCB8F59-CB4A-4F2F-8E3D-16495BBF9F78

Q42947260-654AD758-973F-4D91-92FF-71931636E748

Q42947260-C9F87C19-04BF-458C-BE54-A086B223D549

P577

Q42947260-2B0D3CC6-91B5-4FDB-9F9A-64FA9E4F0972

P5875

Q42947260-E9E6AFAD-D309-4EA8-A7B0-2C4E71877D41

P698

Q42947260-F3E6E881-D3C3-4B70-B23F-5A45175BE876

P356

P1433

P1476

Early on-treatment prediction ...... sing HBsAg and HBV DNA levels.

@en

P2093

Anneke J Van Vuuren

http://www.w3.org/2001/XMLSchema#string

Charles A B Boucher

http://www.w3.org/2001/XMLSchema#string

Elke Verhey

http://www.w3.org/2001/XMLSchema#string

Fehmi Tabak

http://www.w3.org/2001/XMLSchema#string

Harry L A Janssen

http://www.w3.org/2001/XMLSchema#string

Meral Akdogan

http://www.w3.org/2001/XMLSchema#string

Peter Ferenci

http://www.w3.org/2001/XMLSchema#string

Ulus S Akarca

http://www.w3.org/2001/XMLSchema#string

Vincent Rijckborst

http://www.w3.org/2001/XMLSchema#string

Yilmaz Cakaloglu

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

Chronic hepatitis B: update 2009

Histological grading and staging of chronic hepatitis

Hepatitis B e antigen-negative chronic hepatitis B.

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants.

Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

Treatment predictors of a sustained virologic response in hepatitis B and C.

P304

454-461

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.23722

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

Martijn J ter Borg

Yilmaz Cakaloglu

Vincent Rijckborst

Krzysztof Simon

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45495282

http://www.w3.org/2001/XMLSchema#string

P698

20683945

http://www.w3.org/2001/XMLSchema#string